Celgene China Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially joined Celgene on January 1st, 2011. Before that, I worked for Abraxis BioScience, a US-based biopharmaceutical company, which entered China…
Celgene Australia In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that the number of listings has decreased to a point where Australia is in danger of losing its attractiveness as an…
Celgene Australia “Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008. Since then, what have been the highlights in the Celgene development in this part of the world? When Celgene decided…
ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…
Eurogentec Belgium Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the business model of the life sciences industry? The pharmaceutical industry is increasingly being under pressure by the rising costs of…
TiGenix - Belgium Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to make such a dramatic and bold shift in your professional life? I was young and ambitious and despite having a…
Amgen Belgium Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is a relatively young biotechnology company with just over 30 years of experience in the industry. Amgen entered the Belgian market…
Generic Medicines Industry Association (GMiA) In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We have been focusing on several strategic priorities over the past four years, firstly on creating a viable commercial environment for…
Biogen Idec Czech Republic Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology, with a specialization in microbiology. I worked for approximately three years doing clinical work in this field at a hospital,…
Amgen Czech Republic Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us as a ‘wild’ time, with little regulation and easy growth. Since then, the Czech pharma market became much more complex…
FeBelGen Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing the generic and biosimilar drugs industry in Belgium? When I started to head FeBelGen in 2006, my goal/objective was –…
Stallergenes Czech Republic Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did you decide to move down the value chain to a smaller, considerably more specialized biopharmaceutical company like Stallergenes, and what…
See our Cookie Privacy Policy Here
